title: Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.
abstract: Interleukin (IL)-6 is a pro-inflammatory cytokine that produces multifunctional effects. Deregulated IL-6 production and signaling are associated with chronic inflammatory diseases, auto-immunity and cancer. On this basis, inhibition of IL-6 production, its receptors or the signaling pathways are strategies currently being widely pursued to develop novel therapies for a wide range of diseases. This survey aims to provide an updated account of why IL-6 inhibitors are shaping up to become an important class of drugs potentially useful in the treatment of ailments and in particular in inflammation and cancer. In addition we discuss the role of different agents in modulating IL-6 and also recent clinical studies targeting IL-6 in inflammation-mediated diseases and cancer.
authors.affiliation: University of New South Wales, Department of Surgery, St George Hospital (SESIAHS), Sydney, NSW 2217, Australia. z3303886@student.unsw.edu.au
authors.forename: Parvin
authors.initials: P
authors.lastname: Ataie-Kachoie
authors.forename: Mohammad H
authors.initials: MH
authors.lastname: Pourgholami
authors.forename: David L
authors.initials: DL
authors.lastname: Morris
mesh_terms: D000818:Animals; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology*; D015850:Interleukin-6 / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology*; D015398:Signal Transduction; D000093242:Interleukin-6 Inhibitors
chemical_list: D015850:Interleukin-6; D000093242:Interleukin-6 Inhibitors